Skip to main content

Exciting New Data Presented on NSCLC at AACR 2021

AACR & ASCO 2021 Midyear Review
Conference Correspondent
David Spigel, MD
Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Dr David Spigel discusses key presentations on immunotherapy and targeted therapy in the neoadjuvant and adjuvant settings in NSCLC.

Related Items

Comparison of Aumolertinib and Gefitinib in First-Line Treatment of EGFR-Mutated NSCLC
Conference Correspondent
AACR & ASCO 2021 Midyear Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Conference Correspondent
AACR & ASCO 2021 Midyear Review
Anti–PD-L1 Therapy in Combination with Chemotherapy versus Immunotherapy Alone in First-Line NSCLC with PD-L1 Score 1% to 49%
Conference Correspondent
AACR & ASCO 2021 Midyear Review
Pooled Analyses of Immune-Related Adverse Events and Efficacy from IMpower130, IMpower132, and IMpower150
Conference Correspondent
AACR & ASCO 2021 Midyear Review